BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its Simoa® SARS-CoV-2 N Protein Antigen Test that can be run on the Simoa HD-X Analyzer®, a fully automated high-throughput immunoassay instrument.
The Simoa SARS-CoV-2 N Protein Antigen Test detects the presence of the SARS-CoV-2 virus nucleocapsid protein (or N protein) which is known to be elevated in respiratory fluids during the initial acute phase of the infection. Direct detection of antigen proteins from the virus may be a more meaningful measure of infection status than detection of RNA by rRT-PCR because genetic material can linger even after the virus has left the body, resulting in increased risk of false positives1. In clinical studies, the test demonstrated a sensitivity of 97.7% (positive percent agreement) and specificity of 100% (negative percent agreement) up to 14 days following onset of symptoms.
Under the current EUA, the SARS-CoV-2 N Protein Antigen Test is intended for use with nasopharyngeal (NP) samples in individuals suspected of COVID-19 by their healthcare providers. Quanterix will be pursuing authorization for additional sample types, including nasal swabs, saliva, and capillary dried blood obtained from a fingerstick. Preliminary clinical research studies suggest the viral antigen may be readily detectable in asymptomatic and pre-symptomatic patients, and Quanterix is exploring extending the test to screening applications, home-based sample collection and pooling to enable larger scale testing.
FDA authorization of the Simoa SARS-CoV-2 N Protein Antigen Test for NP samples is an important early step in a project funded by the NIH Rapid Acceleration of Diagnostics (RADx) initiative to apply Simoa digital biomarker technology to decentralized SARS-CoV-2 antigen detection in non-invasive sample types. An ultimate aim of this NIH program is to improve clinical laboratory tests that will increase the capacity of SARS-CoV-2 testing in the U.S.
“As case counts and positivity rates rise globally, the COVID-19 testing landscape is of critical importance,” said Kevin Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix and Founder, Powering Precision Health (PPH). “Antigen viral levels, if precisely tested, are potentially a better measure of active infection, and for understanding the kinetics and distribution of viral load across different sample types over the duration of the infection, treatment and recovery. We are pleased to announce a test that not only provides high levels of sensitivity and specificity, but is economical, well suited for high throughput testing and utilizes a complementary supply chain helping efforts to scale testing.”
Simoa RUO assays for COVID-19 Research
Quanterix offers a family of assays tailored to RUO applications. In addition to its EUA assay, Quanterix today also announced the release of the SARS-CoV-2 N Protein Antigen Advantage Assay, tailored for Research Use. This quantitative ultra-sensitive assay is directed to research applications in sample matrices including NP swabs, nasal swabs, serum, plasma, capillary dried blood, and saliva. The assay complements the quantitative Simoa SARS-CoV-2 IgG antibody assay recently introduced for the HD-X instrument which enables researchers to measure both the virus and immune response from the same samples including blood obtained by minimally invasive fingerstick collection.
“In addition to direct viral antigen and antibody detection capabilities, researchers around the world require the most sensitive and specific assays for both immune monitoring and disease profiling applications,” said Hrusovsky. “Our expanded RUO portfolio of ultrasensitive assays also includes customizable panels of up to 10 critical biomarkers for cytokine and chemokine profiling and for carefully monitoring cytokine storms. Our team is working diligently to facilitate research being done on patients with non-resolving immune responses (or COVID-19 long haulers), as well as those with associated vascular and neurological effects. Blood-based biomarkers including antigen, IgG, Nf-L, GFAP, in addition to angiogenesis panels can accurately quantify viral load, immune response, organ damage and level of inflammation from minimally invasive samples at ultra-sensitive levels.”
Simoa (single molecule array technology) is a revolutionary digital approach to immunoassays which allows single molecules to be counted for protein biomarker research applications, changing the way in which the biology of health and disease is studied by giving scientists the ability to closely examine critical biomarkers. In doing so, Quanterix enables development of methods providing much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for applications in a majority of therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease.
For more information on Quanterix’ Simoa technology, visit https://www.quanterix.com/technology. To learn more about Quanterix’ infectious disease research and RUO assay development solutions, visit https://www.quanterix.com/therapeutic-areas/infectious-disease.
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa®, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.